Claims for Patent: 7,166,602

Summary for Patent: 7,166,602

Title:	Pyrazolotriazines as kinase inhibitors
Abstract:	In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]triazine compounds as inhibitors of kinases such as, for example, cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the kinases using such compounds or pharmaceutical compositions.
Inventor(s):	Guzi; Timothy J. (Chatham, NJ), Paruch; Kamil (Garwood, NJ)
Assignee:	Schering Corporation (Kenilworth, NJ)
Application Number:	11/335,383
Patent Claims:	1. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of the following formula, or a pharmaceutically acceptable salt, or ester of said compound, in combination with at least one pharmaceutically acceptable carrier; ##STR00224## wherein: R.sup.1 is selected from the group consisting of H, alkyl, aryl, heteroaryl, heteroarylalkyl, arylalkyl, NR.sup.6R.sup.7, cycloalkyl and cycloalkylalkyl, wherein each of said alkyl, aryl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl and arylalkyl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each being independently selected from the group consisting of halo, alkyl, aryl, heteroaryl, heterocyclyl, trifluoromethyl, OR.sup.6, NR.sup.6R.sup.7, SR.sup.6, SO.sub.2R.sup.6, CN, SO.sub.2N(R.sup.6R.sup.7) and NO.sub.2; R.sup.2 is alkyl, cycloalkyl, alkenyl, alkynyl, trifluoromethyl, --OR.sup.7, --SR.sup.7, hydroxyalkyl, haloalkyl, aryl, heteroaryl, halo, CN, formyl, nitro, alkylcarbonyl, aralkylcarbonyl, heteroaralkylcarbonyl, or -alkylene-N(R.sup.6R.sup.9) (where R.sup.8 and R.sup.9 independently represent H or alkyl, or R.sup.8 and R.sup.9 taken together with the nitrogen in --N(R.sup.8R.sup.9) form a five- to seven- membered heterocycle); ##STR00225## alkyl, alkylthio, aralkylthio, alkylsulfinyl, or aralkylsulfinyl; R.sup.4 is alkyl, cycloalkyl or heterocyclyl, wherein each of said alkyl, cycloalkyl and heterocyclyl can be unsubstituted or optionally independently substituted with 1 4 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, trifluoromethyl, OR.sup.6, NR.sup.6R.sup.7, SR.sup.6, SO.sub.2R.sup.6, CN, SO.sub.2N(R6R7) and NO.sub.2; R.sup.5 is H, alkyl, aryl, heteroaryl, arylalkyl, cycloalkyl, heterocyclyl, acyl or heteroarylalkyl; R.sup.6 is H, alkyl or aryl; R.sup.7 is H or alkyl; R.sup.10 is halo, alkyl, hydroxyalkyl, trifluoromethyl, OR.sup.6, NR.sup.8R.sup.7, SR.sup.6, SO.sub.2R.sup.6, CN, SO.sub.2N(R.sup.6R.sup.7) or NO.sub.2; and n is 0 to 4, and when n is 2 4, the n moieties can be the same or different, each being independently selected, with the following provisos: (i) that when R.sup.2 is C.sub.1 C.sub.4 alkyl and R.sup.5 is H, then R.sup.4 is not a C.sub.1 C.sub.4 alkyl; (ii) that when R.sup.2 is halo, CN, formyl, nitro, alkylcarbonyl, aralkylcarbonyl, heteroaralkylcarbonyl, or -alkylene-N(R.sup.8R.sup.9), then: (a) R.sup.3 is not H, alkylthio, aralkylthio, alkylsulfinyl, aralkylsulfinyl, or --NR.sup.4R.sup.5, and (b) n is not 0; and (iii) that when R.sup.2 is alkyl, cycloalkyl, alkenyl or alkynyl, then R.sup.3 is not NH(methyl), N ,N(dimethyl), NH(acetyl), N(methyl)(acetyl), H, alkyl, alkylthio, aralkylthio, alkylsulfinyl, or aralkylsulfinyl. 2. The pharmaceutical composition of claim 1, additionally comprising one or more agents selected from the group consisting of cytostatic agent, cisplatin, doxorubicin, taxotere, taxol, etoposide, irinotecan, camptostar, topotecan, paclitaxel, docetaxel, epothilones, tamoxifen, 5-fluorouracil, methoxtrexate, 5FU, temozolomide, cyclophosphamide, SCH 66336, R115777, L778,123, BMS 214662, Iressa, Tarceva, antibodies to EGFR, Gleevec, intron, ara-C, adriamycin, cytoxan, gemcitabine, Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, Pentostatine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17.alpha.-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, CPT-11, Anastrazole, Letrazole, Capecitabine, Reloxafine, Droloxafine, or Hexamethylmelamine. 3. A pharmaceutical composition comprising one or more compounds selected from: ##STR00226## ##STR00227## or a pharmaceutically acceptable salt, or ester thereof. 4. The pharmaceutical composition of claim 3, additionally comprising one or more agents selected from the group consisting of cytostatic agent, cisplatin, doxorubicin, taxotere, taxol, etoposide, irinotecan, camptostar, topotecan, paclitaxel, docetaxel, epothilones, tamoxifen, 5-fluorouracil, methoxtrexate, 5FU, temozolomide, cyclophosphamide, SCH 66336, R115777, L778,123, BMS 214662, Iressa, Tarceva, antibodies to EGFR, Gleevec, intron, ara-C, adriamycin, cytoxan, gemcitabine, Uracil , Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, Pentostatine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17.alpha.-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, CPT-11, Anastrazole, Letrazole, Capecitabine, Reloxafine, Droloxafine, or Hexamethylmelamine.

Details for Patent 7,166,602

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2024-02-25
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2024-02-25
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2024-02-25
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2024-02-25